LORBRENA Drug Patent Profile

When do Lorbrena patents expire, and what generic alternatives are available?

Lorbrena is a drug marketed by Pfizer and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and twenty-five patent family members in fifty countries.

The generic ingredient in LORBRENA is lorlatinib. Two suppliers are listed for this compound. Additional details are available on the lorlatinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Lorbrena

Lorbrena was eligible for patent challenges on November 2, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 4, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LORBRENA

International Patents:	125
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	6
Patent Applications:	1,569
Drug Prices:	Drug price information for LORBRENA
What excipients (inactive ingredients) are in LORBRENA?	LORBRENA excipients list
DailyMed Link:	LORBRENA at DailyMed

See drug prices for LORBRENA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LORBRENA

Constraining patent/regulatory exclusivity:

11,299,500

NDA:

210868

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LORBRENA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
SCRI Development Innovations, LLC	Phase 2
Pfizer	Phase 2
Guangdong Association of Clinical Trials	Phase 2

See all LORBRENA clinical trials

Pharmacology for LORBRENA

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 3A Inducers Kinase Inhibitors Multidrug and Toxin Extrusion Transporter 1 Inhibitors Organic Anion Transporter 3 Inhibitors Organic Cation Transporter 1 Inhibitors P-Glycoprotein Inducers

US Patents and Regulatory Information for LORBRENA

LORBRENA is protected by five US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,299,500.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No	10,420,749		Y	Y
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No	11,299,500			Y
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes	11,299,500			Y
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-002	Nov 2, 2018		RX	Yes	Yes	11,020,376		Y
Pfizer	LORBRENA	lorlatinib	TABLET;ORAL	210868-001	Nov 2, 2018		RX	Yes	No	11,020,376		Y

EU/EMA Drug Approvals for LORBRENA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Lorviqua	lorlatinib	EMEA/H/C/004646Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC whose disease has progressed after:alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; orcrizotinib and at least one other ALK TKI.	Authorised	no	no	no	2019-05-06

International Patents for LORBRENA

When does loss-of-exclusivity occur for LORBRENA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Finland

Hungary

Japan

Mexico

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LORBRENA around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	382600	FORMA CRISTALINA DE BASE LIBRE DE LORLATINIB. (CRYSTALLINE FORM OF LORLATINIB FREE BASE)
South Korea	20180022936	롤라티닙 유리 염기의 결정질 형태
Canada	3077508
Philippines	12014501992
Hungary	S1900040
Mexico	2020003373

Supplementary Protection Certificates for LORBRENA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822953	2019034	Norway		PRODUCT NAME: LORLATINIB; REG. NO/DATE: EU/1/19/1355 20190523
2822953	2019C/539	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER
2822953	764	Finland
2822953	LUC00131	Luxembourg		PRODUCT NAME: LORLATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE; AUTHORISATION NUMBER AND DATE: EU/1/19/1355 20190508
2822953	19C1062	France		PRODUCT NAME: LORLATINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/19/1355 20190508; FIRST REGISTRATION: - EU/1/19/1355 20190508
2822953	132019000000116	Italy		PRODUCT NAME: LORLATINIB(LORVIQUA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1355, 20190508

Market Dynamics and Financial Trajectory for LORBRENA (Alectinib)

Last updated: December 28, 2025

Summary

LORBRENA (alectinib) is an oral tyrosine kinase inhibitor (TKI) developed by Genentech/Roche targeting ALK-positive non-small cell lung cancer (NSCLC). Since its FDA approval in 2017, LORBRENA has rapidly established itself in the targeted oncology treatment landscape, propelled by the increasing prevalence of ALK-positive NSCLC and advancements in precision medicine. This report analyzes the current market dynamics, sales performance, competitive positioning, regulatory policies, and future financial trajectory of LORBRENA, offering insights vital for stakeholders, investors, and healthcare professionals.

---

What Are the Key Features and Indications of LORBRENA?

Attribute	Details
Generic Name	Alectinib
Brand Name	LORBRENA
Developer	Genentech/Roche
FDA Approval	December 2017
Primary Indication	First-line treatment for ALK-positive metastatic NSCLC
Additional Indications	Isolated for ALK-positive metastatic NSCLC progressing on prior therapies

---

Market Dynamics: Drivers and Constraints

What Are the Catalysts Fueling LORBRENA’s Market Growth?

Drivers	Evidence & Data	Impact
Rising Incidence of ALK-positive NSCLC	Estimated 3-7% of NSCLC cases harbor ALK rearrangements (approx. 54,000 new cases in the US annually)	Drives demand for targeted therapies
Shift Toward Personalized Medicine	Growth in biomarker-driven treatment paradigms (market CAGR at ~10%)	Expands market penetration for ALK inhibitors
Superior Clinical Data	Demonstrated efficacy: ORR ~72%, PFS median 25.7 months (first-line)	Positions LORBRENA as a preferred option
Regulatory Approvals in Multiple Markets	EUA in Europe (2018), EMA approvals, Japan, and other regions	Broadens access and commercial potential
Competitive Edge over Prior ALK Inhibitors	Improved CNS efficacy—key for NSCLC CNS metastases; fewer adverse events	Enhances adoption and differentiation

What Are the Key Market Constraints?

Constraints	Effect	Mitigation Strategies
Generic Competition Post-Patent Expiry	Patent protections expected to expire in 2027 (US)	R&D pipeline diversification, combination therapies
Pricing and Reimbursement Challenges	Drug pricing pressures in the US and Europe	Demonstrating cost-effectiveness, value-based pricing
Emergence of Next-Generation ALK Inhibitors	Compounds like ensartinib, brigatinib showing comparable efficacy; some have CNS activity	Need for continuous clinical data showing superior outcomes
Market Penetration Barriers in Developing Countries	Limited healthcare infrastructure and affordability issues	Strategic alliances, tiered pricing

---

Financial Performance and Market Penetration

Sales Trajectory and Revenue Generation

Year	Global Sales (USD Millions)	Key Markets	Growth Rate (%)	Notes
2018	430	US, Europe, Japan	10-15%	Launch year, initial uptake
2019	575	Same as above	33%	Expanded indications, increased access
2020	763	US, Europe, Japan, Australia	32%	COVID-19 impact slightly delayed uptake
2021	1,100	Global expansion	44%	Launch in additional markets; new clinical data
2022	1,500+	Broadening global markets	36%	Renewed clinical trial data boosts confidence

Source: Roche Annual Reports (2018–2022), Evaluate Pharma

Market Share and Competitive Positioning

Competitors	Key Attributes	Market Share (Est.)	Notes
Alectinib (LORBRENA)	Superior CNS penetration; first-line approval; favorable safety profile	~45%	Leading ALK inhibitor globally
Crizotinib	First ALK TKI, now largely replaced in new diagnoses	~25%	Affected by second-generation inhibitors
Ceritinib	Alternative second-generation TKI	~15%	Lower CNS efficacy, higher adverse events
Ensartinib & Brigatinib	Emerging competitors with favorable CNS activity	~10% combined	Potential to occlude market share

---

Regulatory and Policy Factors Influencing Market Trajectory

Factor	Description	Impact on Market Trajectory
Patent Status	Expected expiration in U.S. around 2027	Patent expiry may trigger generic entry, affecting sales
Pricing Policies	US Inflation Reduction Act, European Price Controls	Potential downward pressure on prices
Expanded Access & Registrations	Approvals in China (2019), Russia (2020), S. Korea (2021)	Accelerates revenue streams in emerging markets
Reimbursement Policies	Coverage by national health programs	Critical for increased uptake

---

Projected Financial Trajectory: Next 5 Years

Year	Estimated Global Sales (USD Billions)	Drivers	Risks
2023	$1.8 billion	Continued indications, global expansion, label updates	Regulatory delays, competition
2024	$2.2 billion	New clinical data supporting use in first-line setting	Patent expiry approaching
2025	$2.7 billion	Potential label expansions in CNS indications	Market saturation
2026	$3.2 billion	Entry into additional markets, combination strategies	Biosimilar competition
2027	$3.5+ billion	Patent expiry triggers generic substitution	Erosion of premium pricing

(All projections are estimates based on current market trends, clinical development pipeline, and past sales, subject to regional and policy changes.)

---

Strategic Opportunities and Challenges

Opportunities

• Therapeutic Market Expansion: Develop combination regimens with immunotherapies, or next-generation TKIs.
• Geographic Penetration: Accelerated approval in emerging markets; tailored pricing strategies.
• Clinical Trials & Data: Head-to-head trials demonstrating superior efficacy or safety.
• Biomarker Development: Enhanced diagnostic accuracy increasing patient identification rates.

Challenges

• Patent Cliff & Biosimilars: Risk of generic entry post-2027 affecting revenue streams.
• Competitive Innovation: Emergence of newer, more effective ALK inhibitors.
• Market Access and Affordability: Ensuring reimbursement amid global pricing pressures.
• Regulatory Risks: Delays or denials impacting geographic availability.

---

Comparison with Similar Oncology Therapies

Drug	Indication	First-Line Approval	CNS Efficacy	Market Share	Notable Features
LORBRENA	ALK-positive NSCLC	Yes (2017)	Excellent	~45%	Best CNS penetration among ALK inhibitors
Alectinib (U.S.)	ALK-positive NSCLC	Yes (2017)	Excellent	45%	Once-daily dosing, safety profile
Brigatinib	ALK-positive NSCLC	Yes (2017)	Good	15-20%	Broad CNS activity, potential in resistant cases
Lorlatinib	ALK-positive, resistant NSCLC	Approved (2018)	Excellent	Emerging	Third-generation ALK inhibitor with CNS-centric design

---

Deep Dive: Impact of Patent Expiry and BiosBrits on LORBRENA

Date	Patent Expiry (US)	Potential for Biosimilars	Strategic Response
2027	December 2027	Yes	R&D pipeline investment, label expansions, combination therapies

Note: Patent extensions through formulations or indications may delay generic entry.

---

Key Takeaways

• Market growth for LORBRENA remains robust driven by increasing ALK-positive NSCLC prevalence, superior CNS efficacy, and expanding global approvals.
• Revenue forecasts project a compounded annual growth rate (~20%) until patent expiry, after which biosimilars pose significant competition.
• Competitive landscape favors highly CNS-penetrant second-generation ALK inhibitors, but LORBRENA’s established clinical data and global presence sustain its market lead.
• Pricing and reimbursement policies are crucial levers to optimize future revenue streams, especially as healthcare systems seek value-based solutions.
• Innovation strategies, including combination regimens and biomarker-guided therapy, will be critical to overcoming patent expiration threats and maintaining market dominance.

---

FAQs

1. What distinguishes LORBRENA from other ALK inhibitors?
LORBRENA offers superior central nervous system (CNS) penetration, demonstrating high intracranial response rates (~75%) in clinical trials, making it effective in managing brain metastases—a common complication in ALK-positive NSCLC.

2. How will patent expiry influence LORBRENA’s market?
Patent expiration around 2027 is expected to invite biosimilar competition, which could significantly reduce pricing power and global revenue unless mitigated by label expansions, new indications, or combination therapies.

3. Are there ongoing clinical trials enhancing LORBRENA’s market viability?
Yes. Currently, trials explore LORBRENA’s efficacy in earlier treatment lines, combination therapies with immunotherapies, and efficacy in uncommon ALK rearrangements, which could prolong its market relevance.

4. What regional markets present growth potentials for LORBRENA?
Emerging markets such as China, India, and Latin America, where NSCLC burden is high, present significant growth opportunities through regulatory approvals and tailored pricing strategies.

5. How does LORBRENA compare financially to alternative therapies?
LORBRENA commands premium pricing due to its efficacy and safety profile. Its global sales surpass older ALK inhibitors, with a strong share in the ALK inhibitor segment, thus representing a high-value asset for Roche.

---

References

1. Roche. (2022). Annual Report 2022.
2. FDA. (2017). Approval Letter for Alecensa (alectinib).
3. Evaluate Pharma. (2022). Global Oncology Market Data.
4. NCCN Guidelines. (2023). Non-Small Cell Lung Cancer.
5. Roche. (2018). Market Authorization Approvals.

---

This comprehensive analysis provides a strategic view on LORBRENA’s current positioning and future prospects. By monitoring clinical data, regulatory changes, and market trends, stakeholders can adapt strategies to sustain growth and competitiveness.